FULC
Price
$6.52
Change
+$0.11 (+1.72%)
Updated
Sep 3 closing price
Capitalization
352.14M
69 days until earnings call
MDXG
Price
$7.10
Change
-$0.09 (-1.25%)
Updated
Sep 3 closing price
Capitalization
1.05B
55 days until earnings call
Interact to see
Advertisement

FULC vs MDXG

Header iconFULC vs MDXG Comparison
Open Charts FULC vs MDXGBanner chart's image
Fulcrum Therapeutics
Price$6.52
Change+$0.11 (+1.72%)
Volume$224.79K
Capitalization352.14M
MiMedx Group
Price$7.10
Change-$0.09 (-1.25%)
Volume$448.68K
Capitalization1.05B
FULC vs MDXG Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. MDXG commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a StrongBuy and MDXG is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (FULC: $6.52 vs. MDXG: $7.10)
Brand notoriety: FULC and MDXG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 33% vs. MDXG: 57%
Market capitalization -- FULC: $352.14M vs. MDXG: $1.05B
FULC [@Biotechnology] is valued at $352.14M. MDXG’s [@Biotechnology] market capitalization is $1.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileMDXG’s FA Score has 1 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • MDXG’s FA Score: 1 green, 4 red.
According to our system of comparison, FULC is a better buy in the long-term than MDXG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 6 TA indicator(s) are bullish while MDXG’s TA Score has 2 bullish TA indicator(s).

  • FULC’s TA Score: 6 bullish, 4 bearish.
  • MDXG’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, FULC is a better buy in the short-term than MDXG.

Price Growth

FULC (@Biotechnology) experienced а -1.66% price change this week, while MDXG (@Biotechnology) price change was -0.98% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

MDXG is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDXG($1.05B) has a higher market cap than FULC($352M). FULC YTD gains are higher at: 38.723 vs. MDXG (-26.195). MDXG has higher annual earnings (EBITDA): 52.7M vs. FULC (-81.28M). FULC has more cash in the bank: 214M vs. MDXG (119M). FULC has less debt than MDXG: FULC (7.57M) vs MDXG (18.5M). MDXG has higher revenues than FULC: MDXG (364M) vs FULC (0).
FULCMDXGFULC / MDXG
Capitalization352M1.05B33%
EBITDA-81.28M52.7M-154%
Gain YTD38.723-26.195-148%
P/E RatioN/A33.81-
Revenue0364M-
Total Cash214M119M180%
Total Debt7.57M18.5M41%
FUNDAMENTALS RATINGS
FULC vs MDXG: Fundamental Ratings
FULC
MDXG
OUTLOOK RATING
1..100
6910
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10090
SMR RATING
1..100
9751
PRICE GROWTH RATING
1..100
4856
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
3690

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (22) in the null industry is somewhat better than the same rating for MDXG (68) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than MDXG’s over the last 12 months.

MDXG's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as FULC (100) in the null industry. This means that MDXG’s stock grew similarly to FULC’s over the last 12 months.

MDXG's SMR Rating (51) in the Biotechnology industry is somewhat better than the same rating for FULC (97) in the null industry. This means that MDXG’s stock grew somewhat faster than FULC’s over the last 12 months.

FULC's Price Growth Rating (48) in the null industry is in the same range as MDXG (56) in the Biotechnology industry. This means that FULC’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for FULC (100) in the null industry. This means that MDXG’s stock grew significantly faster than FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCMDXG
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 7 days ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 15 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDXG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMTV22.580.01
+0.07%
Community Bancorp.
SQNXF66.78N/A
N/A
Square Enix Co., Ltd.
TRUBF4.87N/A
N/A
TRUECALLER AB
EVCO2.00N/A
N/A
Everest Consolidator Acquisition Corporation
UNCFF76.50-1.17
-1.50%
UniCredito Spa

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ANNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+1.72%
ANNX - FULC
40%
Loosely correlated
-0.97%
VRDN - FULC
40%
Loosely correlated
+1.72%
RARE - FULC
39%
Loosely correlated
-1.50%
MRNA - FULC
38%
Loosely correlated
-0.58%
BMRN - FULC
38%
Loosely correlated
-0.19%
More

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with INM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then INM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
-1.25%
INM - MDXG
38%
Loosely correlated
-2.31%
PCVX - MDXG
36%
Loosely correlated
+1.71%
MGNX - MDXG
36%
Loosely correlated
+9.77%
CTMX - MDXG
32%
Poorly correlated
+1.92%
FULC - MDXG
32%
Poorly correlated
+1.72%
More